Health Condition 1: C220- Liver cell carcinoma Health Condition 2: K703- Alcoholic cirrhosis of liver Health Condition 3: K721- Chronic hepatic failure Health Condition 4: K730- Chronic persistent hepatitis, notelsewhere classified Health Condition 5: K704- Alcoholic hepatic failure Health Condition 6: K712- Toxic liver disease with acute hepatitis Health Condition 7: K742- Hepatic fibrosis with hepatic sclerosis Health Condition 8: K766- Portal hypertension Health Condition 9: K720- Acute and s
Conditions
Interventions
Intervention1: Tablet Ecosprin 75mg: Patients will be randomised (1:1) into 2 groups (‘Aspirin’ group and ‘no aspirin’ groups) after 2 weeks of transplant if platelets = 50,000 /ul.
According to rand
Sponsors
Amrita Institute of Medical sciences
Eligibility
Inclusion criteria
Inclusion criteria: All patients who are undergoing LDLT in our institute
Exclusion criteria
Exclusion criteria: 1 . Paediatric patients (age 2. Re-transplantations 3. Patients not willing to participate in the study 4. If PLT 5. Multiorgan transplants
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcomes : Occurrence of ACR both biopsy proven & clinically suspected.Timepoint: 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Hepatic artery patency 2.Postoperative complications 3. Graft survival 4. Patient survival 5. Tumour recurrence for HCC patientsTimepoint: 6 months | — |
Countries
India
Contacts
Public ContactBhanoo Tej Bathala
Amrita Institute of Medical Sciences
Outcome results
None listed